{"id":550369,"date":"2020-05-31T00:00:00","date_gmt":"2020-05-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0008-2019-biopharma-osteoarthritic-pain-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-03-31T10:45:05","modified_gmt":"2026-03-31T10:45:05","slug":"dlsfcg0008-2019-biopharma-osteoarthritic-pain-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0008-2019-biopharma-osteoarthritic-pain-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Osteoarthritic Pain | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug developers given the persistent unmet need for more effective and safe therapies, particularly those with a novel and distinct mechanism of action that strongly correlates with the nature of this type of pain. OA pain is predominantly treated with cost-effective generic NSAIDs and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics, new combinations of existing NSAIDs that attempt to mitigate side effects, and intra-articular injections are also frequently prescribed in later lines of therapy. Emerging therapies, such as biological drugs from Pfizer \/ Eli Lilly and Regeneron \/ Teva \/ Mitsubishi Tanabe Pharma targeting NGF, and the increasing number of patients diagnosed with OA pain due to lifestyle influences will be key drivers for growth through 2028.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How do interviewed experts perceive the OA pain marketplace to be changing given the emphasis on the risk of abuse \/ misuse with opioid analgesics?<\/li>\n<li>What effect will the recent launches of new analgesics such as Flexion Therapeutics&#8217; Zilretta and Iroko\u2019s Vivlodex continue to have on the treatment paradigm?<\/li>\n<li>What will the impact of a new drug class, the anti-NGF biologics, be on the treatment landscape given their demonstrably robust efficacy tempered by lingering concerns about safety issues seen in clinical trials?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research: <\/strong>Thirteen country-specific interviews with thought-leading pain specialists and rheumatologists, supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence and drug-treated rates of OA pain by country.<\/p>\n<p><strong>Emerging therapies: <\/strong>Phase III \/ preregistration \/ registration: 8 drugs; Phase II: 7 drugs; coverage of select Phase I products.<\/p>\n<p><strong>Market forecast features: <\/strong>10-year, annualized, drug-level sales and patient share of key analgesics through 2028, segmented by brands \/ generics.<\/p>\n<p><strong>Key companies: <\/strong>Acorda Therapeutics, Ampio Pharmaceuticals, Astellas, Centrexion, Collegium Pharmaceutical, Eli Lilly, Flexion Therapeutics, Iroko Pharmaceuticals, Mitsubishi Tanabe Pharma, Nektar Therapeutics, Pfizer, Purdue Pharma, Regeneron, Samumed, Teva.<\/p>\n<p><strong>Key drugs: <\/strong>acetaminophen \/ hydrocodone, Ampion, cebranopadol, celecoxib, CNTX-4975, fasinumab, Hysingla ER (hydrocodone ER), lorecivivint, Nucynta IR \/ ER (tapentadol IR \/ ER), oxycodegol (NKTR-181), oxycodone CR (OxyContin, generics), oxycodone ER (Xtampza ER), Qutenza (8% capsaicin patch), tanezumab, tramadol, Vivlodex (meloxicam, low dose), Zilretta (triamcinolone ER, injectable).<\/p>\n<p><strong>Product Description: <\/strong>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-550369","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteoarthritic-pain","biopharma-therapy-areas-osteoarthritis","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/550369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/550369\/revisions"}],"predecessor-version":[{"id":576518,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/550369\/revisions\/576518"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=550369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}